Lupin Limited, through its wholly-owned subsidiary Nanomi B.V., is progressing with its €190 million acquisition of Netherlands-based VISUfarma B.V. Initially expected to close in 2025, the deal is now anticipated to complete by February 2026. The acquisition strengthens Lupin’s European ophthalmology presence and expands its global specialty portfolio.
Global pharmaceutical major Lupin Limited has updated the timeline for its acquisition of VISUfarma B.V., a Netherlands-based specialty ophthalmology company. The €190 million transaction, executed via Lupin’s subsidiary Nanomi B.V., was originally scheduled to conclude by end-2025 but is now anticipated to close by February 2026.
VISUfarma brings a portfolio of over 60 branded eye health products and a strong commercial infrastructure across major European markets. The acquisition aligns with Lupin’s strategy to expand its specialty business globally and strengthen its footprint in ophthalmology.
Key Highlights
-
Transaction Value: €190 million acquisition of VISUfarma B.V.
-
Revised Timeline: Completion anticipated by February 2026
-
Strategic Fit: Expands Lupin’s European ophthalmology presence
-
Portfolio Strength: VISUfarma offers 60+ branded eye health products
-
Global Expansion: Reinforces Lupin’s specialty franchise worldwide
This acquisition underscores Lupin’s commitment to diversifying its global portfolio and enhancing its presence in high-growth therapeutic areas.
Sources: ScanX News, Lupin Corporate Filings